Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $1.3 million.

  • Coherus Oncology's Change in Accured Expenses rose 12532.78% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.6 million, marking a year-over-year increase of 3711.27%. This contributed to the annual value of -$56.9 million for FY2024, which is 62098.56% down from last year.
  • Latest data reveals that Coherus Oncology reported Change in Accured Expenses of $1.3 million as of Q3 2025, which was up 12532.78% from -$6.6 million recorded in Q2 2025.
  • Coherus Oncology's Change in Accured Expenses' 5-year high stood at $40.9 million during Q3 2022, with a 5-year trough of -$47.4 million in Q2 2024.
  • Its 5-year average for Change in Accured Expenses is -$2.1 million, with a median of -$1.4 million in 2022.
  • As far as peak fluctuations go, Coherus Oncology's Change in Accured Expenses surged by 713000.0% in 2021, and later crashed by 231351.35% in 2022.
  • Quarter analysis of 5 years shows Coherus Oncology's Change in Accured Expenses stood at $1.4 million in 2021, then plummeted by 2313.51% to -$31.1 million in 2022, then surged by 163.39% to $19.7 million in 2023, then tumbled by 130.27% to -$6.0 million in 2024, then surged by 121.35% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$6.6 million for Q2 2025, and -$8.3 million during Q1 2025.